Bio-synonyms: describing biosimilars without saying ‘copycats’ or ‘knock-offs’

Terms such as ‘copycats’ and ‘knock-offs’ are inaccurate and misleading, say drug makers. We ask therefore how industry and the media should refer to biosimilar products?

Earlier this year, biosimilar expert and fellow journalist Duncan Emerton expressed his strong dislike to the words ‘copycat’ and ‘knock-off’ when it comes to describing versions of biological products…

Read the full article here ->